MELBOURNE, AUSTRALIA / ACCESSWIRE / July 9, 2015 / Propanc Health Group Corporation (PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced that positive signals have emerged in several pilot animal studies measuring the effects of PRP against several tumor types.
A pilot study is often used to test the design of the full-scale experiment which then can be adjusted. It is a potentially valuable insight and should anything be missing in the pilot study it can be added to the full-scale (and more expensive) experiment to improve the chances of a clear outcome.
For PRP, positive signals emerged from ovarian and two types of pancreatic cancers, where human derived cancer cells were injected into immune-compromised mice and grown over time, followed by treatment with PRP over a defined period. In ovarian cancer, a trend in the reduction of tumor weight, coupled with a reduction in the number of mice with distended (swollen due to pressure from inside) abdomens, most likely related to the size of the tumors, was notable. In two separate pancreatic cancer cell types, similar trends were observed with a reduction of tumor weight.
Importantly, current treatment standards for ovarian and pancreatic cancers are associated with high levels of toxicity. Both cancers also exhibit a high mortality rate for patients when diagnosed. A substantial need exists for more tolerable treatments that can offer patients a meaningful extension and improved quality of life.
Stage two of the dose escalating study is also underway to clearly define a maximum feasible and tolerable dose in mice for further efficacy studies. Interestingly, PRP was successfully dosed at higher concentrations without any adverse clinical signs observed. This means PRP can be dosed at higher levels in future studies, which is expected to increase PRP’s anti-tumor efficacy.
“We are making significant steps towards defining a target therapeutic dose for PRP which can be administered safely in animals and extrapolated to a safe starting dose in humans,” said Dr Julian Kenyon, Propanc’s Chief Scientific Officer. “Undertaking these pilot animal studies continues to provide valuable information which correlates with clinical observations made when I treated late stage patients suffering from similar cancers, and an extension of life was observed in some of these patients. This correlation gives us confidence in selecting our target patient populations when we conduct future human studies.”
“Research and development activities with our research partners into the effects of PRP are progressing well and we are very pleased with the results, especially when PRP responds to cancer types where a real medical need exists,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Furthermore, these activities are providing valuable information which will assist our scientific and clinical experts in determining the right structure for our human trials.”
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. Propanc have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc’s products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, Propanc intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, Propanc intend to development their lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.